Medicare's spending projection on the Alzheimer's drug Leqembi is way higher than Eisai's own estimates. Takeda signed an ...
As for FibroGen’s roxadustat, the drug has fallen victim to a string of setbacks in the U.S. that culminated in late February ...
As industries around the globe wrestle with where and how often artificial intelligence (AI) should be implemented in their ...
This week on “The Top Line,” we're joined by Fierce Biotech Senior Editor Annalee Armstrong and Fierce Pharma Marketing ...
AstraZeneca has tapped an ice hockey player who knows a thing or two about checking for the latest spin on its NHL-partnered ...
The initiative comes nearly two years after the EC launched an investigation surrounding Vifor’s alleged efforts to disparage ...
Immunology is AbbVie’s world, everyone else just lives in it. | Immunology is AbbVie’s world, everyone else just lives in it. That is the takeaway from ZoomRx’s analysis of the perceptions of ...
During a busy period of overhaul at Sanofi, the company is restructuring its U.S. vaccine commercial group. | During a busy ...
After Adstiladrin's FDA approval in late 2022, Ferring Pharmaceuticals finally established unfettered supply of the bladder ...
After proving the merits of its drug delivery platform last year with the approval of Teva’s long-acting schizophrenia drug ...
History is coming full circle as induced pluripotent stem (iPS) cell-derived cell therapy maker Shinobi Therapeutics links up ...
Two weeks after gaining a hard-earned FDA label expansion for its long-established antipsychotic drug Fanapt (iloperidone), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results